Update on the clinical utility of once-daily tacrolimus in the management of transplantation
Maria Aurora Posadas Salas, Titte R Srinivas Division of Nephrology and Hypertension, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA Abstract: Adherence to immunosuppression and minimizing variability in drug exposure are important considerations in preventing reje...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2014-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Maria Aurora Posadas Salas, Titte R Srinivas Division of Nephrology and Hypertension, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA Abstract: Adherence to immunosuppression and minimizing variability in drug exposure are important considerations in preventing rejection and maximizing overall transplant outcomes. The availability of once-daily tacrolimus may confer potential benefit by simplifying immunosuppressive regimens, thereby improving medication adherence among transplant recipients. Pharmacokinetic studies in healthy normal volunteers and stable transplant recipients suggest that once-daily tacrolimus is bioequivalent to twice-daily tacrolimus. Efficacy studies suggest that once-daily tacrolimus is noninferior to twice-daily tacrolimus with a concentration-dependent rejection risk. The incidence of biopsy-proven acute rejection, graft survival, and patient survival are more or less comparable between the two tacrolimus formulations. Once-daily tacrolimus has also been reported to have favorable effects on blood pressure, lipid profile, and glucose tolerance. Once-daily tacrolimus may be a viable option to consider for de novo immunosuppression or for conversion from conventional tacrolimus. Keywords: pharmacokinetics, toxicity, immunosuppression, adherence |
|---|---|
| Item Description: | 1177-8881 |